Revance Therapeutics Accepts Increased Buyout Offer From Crown Laboratories

MT Newswires Live2025-01-22

Revance Therapeutics' (RVNC) board has approved and recommended a revised buyout offer of $3.65 per share in cash, an increase of $0.55, from privately held Crown Laboratories, the companies said Tuesday.

Under their amended and restated merger agreement, which was further amended Friday, Crown also agreed to extend its tender offer for all of Revance's outstanding shares until Feb. 4, according to a joint statement.

As of Friday, about 6.3 million shares, or roughly 6% of outstanding shares, have been validly tendered, the companies said, citing Computershare Trust, depositary for the tender offer.

The companies expect to close their transaction by Feb. 6, they said.

Revance shares were down about 1% in midday trade on Tuesday.

Price: 3.65, Change: -0.04, Percent Change: -0.95

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2505048282?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-22 01:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505048282","market":"us","top_or_hot":-1,"title":"Revance Therapeutics Accepts Increased Buyout Offer From Crown Laboratories","media":"MT Newswires Live","content":"<html><body><p> Revance <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (RVNC) board has approved and recommended a revised buyout offer of $3.65 per share in cash, an increase of $0.55, from privately held Crown Laboratories, the companies said Tuesday.</p><p>Under their amended and restated merger agreement, which was further amended Friday, Crown also agreed to extend its tender offer for all of Revance's outstanding shares until Feb. 4, according to a joint statement.</p><p>As of Friday, about 6.3 million shares, or roughly 6% of outstanding shares, have been validly tendered, the companies said, citing Computershare Trust, depositary for the tender offer.</p><p>The companies expect to close their transaction by Feb. 6, they said.</p><p>Revance shares were down about 1% in midday trade on Tuesday.</p><p>Price: 3.65, Change: -0.04, Percent Change: -0.95</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revance Therapeutics Accepts Increased Buyout Offer From Crown Laboratories</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevance Therapeutics Accepts Increased Buyout Offer From Crown Laboratories\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-22 01:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Revance <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (RVNC) board has approved and recommended a revised buyout offer of $3.65 per share in cash, an increase of $0.55, from privately held Crown Laboratories, the companies said Tuesday.</p><p>Under their amended and restated merger agreement, which was further amended Friday, Crown also agreed to extend its tender offer for all of Revance's outstanding shares until Feb. 4, according to a joint statement.</p><p>As of Friday, about 6.3 million shares, or roughly 6% of outstanding shares, have been validly tendered, the companies said, citing Computershare Trust, depositary for the tender offer.</p><p>The companies expect to close their transaction by Feb. 6, they said.</p><p>Revance shares were down about 1% in midday trade on Tuesday.</p><p>Price: 3.65, Change: -0.04, Percent Change: -0.95</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1803068623.USD","symbol_name":"TEMPLETON GLOBAL CLIMATE CHANGE \"AH1\" (USDHDG) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2505048282","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505048282","pubTimestamp":1737480961,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Revance Therapeutics'  board has approved and recommended a revised buyout offer of $3.65 per share in cash, an increase of $0.55, from privately held Crown Laboratories, the companies said Tuesday.Under their amended and restated merger agreement, which was further amended Friday, Crown also agreed to extend its tender offer for all of Revance's outstanding shares until Feb. 4, according to a joint statement.As of Friday, about 6.3 million shares, or roughly 6% of outstanding shares, have been validly tendered, the companies said, citing Computershare Trust, depositary for the tender offer.The companies expect to close their transaction by Feb. 6, they said.Revance shares were down about 1% in midday trade on Tuesday.Price: 3.65, Change: -0.04, Percent Change: -0.95","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1803068623.USD":"TEMPLETON GLOBAL CLIMATE CHANGE \"AH1\" (USDHDG) ACC","LU1892829315.USD":"FIDELITY FUNDS SUSTAINABLE WATER & WASTE \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","BK4588":"碎股","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4007":"制药","BK4126":"金属与玻璃容器","CCK":"皇冠控股","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","RVNC":"Revance Therapeutics Inc","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"Revance Therapeutics接受Crown Laboratories增加的收购要约","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CCK":1,"RVNC":1},"content_text":"Revance Therapeutics' (RVNC) board has approved and recommended a revised buyout offer of $3.65 per share in cash, an increase of $0.55, from privately held Crown Laboratories, the companies said Tuesday.Under their amended and restated merger agreement, which was further amended Friday, Crown also agreed to extend its tender offer for all of Revance's outstanding shares until Feb. 4, according to a joint statement.As of Friday, about 6.3 million shares, or roughly 6% of outstanding shares, have been validly tendered, the companies said, citing Computershare Trust, depositary for the tender offer.The companies expect to close their transaction by Feb. 6, they said.Revance shares were down about 1% in midday trade on Tuesday.Price: 3.65, Change: -0.04, Percent Change: -0.95","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2505048282","isCrawlerRequest":true}